Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

Phase 2 Recruiting 60 enrolled Emory University Centers for Disease Control and Prevention · collab

RandomizedParallel-groupOpen-labelPrevention

Summary

REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.

Timeline

Start: 2025-01-13
Primary completion: 2026-07
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Allogeneic Microbiota	Other / unclassified	30 ml	Rectal
Subject	Allogeneic Microbiota	Other / unclassified	250 ml	Rectal

Indications

No indication recorded.